Atopic dermatitis is the most common chronic inflammatory skin disease in children and adolescents. The Korean Academy of Pediatric Allergy and Respiratory Disease published the Atopic Dermatitis Treatment Guideline in 2008, which has been helpful in atopic dermatitis treatment until now. Various reports on the development and effectiveness of new drugs have suggested that there is a need to develop and revise old treatment guidelines. Part 1 aimed to provide evidence-based recommendations for skin care management and topical treatment for atopic dermatitis. Part 2 focuses on systemic treatment, novel therapeutics, and adjuvant therapy. The goal of this guideline is intended to assist front-line doctors treating pediatric and adolescent atopic dermatitis patients make safer, more effective, and more rational decisions regarding systemic treatment, novel therapeutics, and adjuvant therapy by providing evidence-based recommendations with a clear level of evidence and benefit regarding treatment.

Atopic dermatitis is the most common chronic inflammatory skin disease in children and adolescents. The Korean Academy of Pediatric Allergy and Respiratory Disease published the Atopic Dermatitis Treatment Guideline in 2008, which has been helpful in atopic dermatitis treatment until now. Various reports on the development and effectiveness of new drugs have suggested that there is a need to develop and revise old treatment guidelines. Part 1 aimed to provide evidence-based recommendations for skin care management and topical treatment for atopic dermatitis. Part 2 focuses on systemic treatment, novel therapeutics, and adjuvant therapy. The goal of this guideline is intended to assist front-line doctors treating pediatric and adolescent atopic dermatitis patients make safer, more effective, and more rational decisions regarding systemic treatment, novel therapeutics, and adjuvant therapy by providing evidence-based recommendations with a clear level of evidence and benefit regarding treatment.

Atopic dermatitis is the most common chronic inflammatory skin disease in children and adolescents. The Korean Academy of Pediatric Allergy and Respiratory Disease published the Atopic Dermatitis Treatment Guideline in 2008, which has been helpful in atopic dermatitis treatment until now. Various reports on the development and effectiveness of new drugs have suggested that there is a need to develop and revise old treatment guidelines. Part 1 aimed to provide evidence-based recommendations for skin care management and topical treatment for atopic dermatitis. Part 2 focuses on systemic treatment, novel therapeutics, and adjuvant therapy. The goal of this guideline is intended to assist front-line doctors treating pediatric and adolescent atopic dermatitis patients make safer, more effective, and more rational decisions regarding systemic treatment, novel therapeutics, and adjuvant therapy by providing evidence-based recommendations with a clear level of evidence and benefit regarding treatment.

Atopic dermatitis is the most common chronic inflammatory skin disease in children and adolescents. The Korean Academy of Pediatric Allergy and Respiratory Disease published the Atopic Dermatitis Treatment Guideline in 2008, which has been helpful in atopic dermatitis treatment until now. Various reports on the development and effectiveness of new drugs have suggested that there is a need to develop and revise old treatment guidelines. Part 1 aimed to provide evidence-based recommendations for skin care management and topical treatment for atopic dermatitis. Part 2 focuses on systemic treatment, novel therapeutics, and adjuvant therapy. The goal of this guideline is intended to assist front-line doctors treating pediatric and adolescent atopic dermatitis patients make safer, more effective, and more rational decisions regarding systemic treatment, novel therapeutics, and adjuvant therapy by providing evidence-based recommendations with a clear level of evidence and benefit regarding treatment.

Atopic dermatitis is the most common chronic inflammatory skin disease in children and adolescents. The Korean Academy of Pediatric Allergy and Respiratory Disease published the Atopic Dermatitis Treatment Guideline in 2008, which has been helpful in atopic dermatitis treatment until now. Various reports on the development and effectiveness of new drugs have suggested that there is a need to develop and revise old treatment guidelines. Part 1 aimed to provide evidence-based recommendations for skin care management and topical treatment for atopic dermatitis. Part 2 focuses on systemic treatment, novel therapeutics, and adjuvant therapy. The goal of this guideline is intended to assist front-line doctors treating pediatric and adolescent atopic dermatitis patients make safer, more effective, and more rational decisions regarding systemic treatment, novel therapeutics, and adjuvant therapy by providing evidence-based recommendations with a clear level of evidence and benefit regarding treatment.

Atopic dermatitis is one of the most common chronic skin inflammatory diseases in children. Appropriate treatment is difficult due to chronic course with frequent exacerbations, especially in children. Treatment requires caution due to a lack of safety data and information regarding the long-term prognosis of management strategies. The Korean Academy of Pediatric Allergy and Respiratory Disease (KAPARD) published the Atopic Dermatitis Treatment Guidelines in 2008, which has been used to direct atopic dermatitis treatment. Accumulating evidence suggests that the guidelines need to be updated regarding bathing methods (duration of bath, temperature, etc.), wet wrap therapy, and topical treatments in line with environmental changes over time and changes in the management strategies of atopic dermatitis. This KAPARD guidelines for atopic dermatitis applied an adaptation based on a systematic review and analysis of selected literature. They are intended to support front-line doctors treating pediatric and adolescent patients with atopic dermatitis in making reasoned, safe, effective empirical treatment decisions. In Part I of the KAPARD guidelines for atopic dermatitis, we included evidence-based skin care management strategies and topical treatment options.

Atopic dermatitis is one of the most common chronic skin inflammatory diseases in children. Appropriate treatment is difficult due to chronic course with frequent exacerbations, especially in children. Treatment requires caution due to a lack of safety data and information regarding the long-term prognosis of management strategies. The Korean Academy of Pediatric Allergy and Respiratory Disease (KAPARD) published the Atopic Dermatitis Treatment Guidelines in 2008, which has been used to direct atopic dermatitis treatment. Accumulating evidence suggests that the guidelines need to be updated regarding bathing methods (duration of bath, temperature, etc.), wet wrap therapy, and topical treatments in line with environmental changes over time and changes in the management strategies of atopic dermatitis. This KAPARD guidelines for atopic dermatitis applied an adaptation based on a systematic review and analysis of selected literature. They are intended to support front-line doctors treating pediatric and adolescent patients with atopic dermatitis in making reasoned, safe, effective empirical treatment decisions. In Part I of the KAPARD guidelines for atopic dermatitis, we included evidence-based skin care management strategies and topical treatment options.

Background and Objectives: Surgical decision-making for papillary thyroid cancer (PTC) relies on accurate preoperative staging, where ultrasonography plays a crucial role in predicting outcomes. We aimed to analyze the predictive effects of preoperative sonographic findings on pathological characteristics. Materials and Methods: Retrospective study was performed using ultrasonographic images and clinico-pathologic data of papillary thyroid cancer patients who underwent total thyroidectomy or lobectomy between March 2016 and May 2020. Finally, 152 patients and 169 tumors were analyzed. Results: Mean age of patients was 54.2±14.2 years and the proportion of female was 75.7%. Tumor size was 13.6±10.3 mm and the proportions of extrathyroidal extension (ETE) and lymph node (LN) involvement were 52.2% and 23.0%, respectively. Preoperative sonographic findings, including ETE, tumor margin, echogenicity, and K-TIRDAS, were significantly associated with pathological ETE.Other pathological characteristics, including LN involvement, lymphovascular invasion, and resection margin positivity, were more observed in patients with more aggressive findings on preoperative sonography; however, we could not find statistical significances. Conclusion This study showed that preoperative sonographic characteristics, such as sonographic ETE, tumor margin, echogenicity, and K-TIRADS, can provide valuable insights into predicting pathological ETE in PTC patients.

Atopic dermatitis is one of the most common chronic skin inflammatory diseases in children. Appropriate treatment is difficult due to chronic course with frequent exacerbations, especially in children. Treatment requires caution due to a lack of safety data and information regarding the long-term prognosis of management strategies. The Korean Academy of Pediatric Allergy and Respiratory Disease (KAPARD) published the Atopic Dermatitis Treatment Guidelines in 2008, which has been used to direct atopic dermatitis treatment. Accumulating evidence suggests that the guidelines need to be updated regarding bathing methods (duration of bath, temperature, etc.), wet wrap therapy, and topical treatments in line with environmental changes over time and changes in the management strategies of atopic dermatitis. This KAPARD guidelines for atopic dermatitis applied an adaptation based on a systematic review and analysis of selected literature. They are intended to support front-line doctors treating pediatric and adolescent patients with atopic dermatitis in making reasoned, safe, effective empirical treatment decisions. In Part I of the KAPARD guidelines for atopic dermatitis, we included evidence-based skin care management strategies and topical treatment options.

Background: s/Aims: Reported incidence of extrahepatic bile duct cancer is higher in Asians than in Western populations. Korea, in particular, is one of the countries with the highest incidence rates of extrahepatic bile duct cancer in the world. Although research and innovative therapeutic modalities for extrahepatic bile duct cancer are emerging, clinical guidelines are currently unavailable in Korea. The Korean Society of Hepato-Biliary-Pancreatic Surgery in collaboration with related societies (Korean Pancreatic and Biliary Surgery Society, Korean Society of Abdominal Radiology, Korean Society of Medical Oncology, Korean Society of Radiation Oncology, Korean Society of Pathologists, and Korean Society of Nuclear Medicine) decided to establish clinical guideline for extrahepatic bile duct cancer in June 2021. Methods: Contents of the guidelines were developed through subgroup meetings for each key question and a preliminary draft was finalized through a Clinical Guidelines Committee workshop. Results: In November 2021, the finalized draft was presented for public scrutiny during a formal hearing. Conclusions The extrahepatic guideline committee believed that this guideline could be helpful in the treatment of patients.